Sugi Predict

Sugi Predict / Compounds / SCHEMBL4087887

SCHEMBL4087887

SCHEMBL4087887

O=C(O)CCNC(=O)c1ccc(CN(CC(c2ccccc2)c2ccccc2)C(=O)c2cc3cc(Cl)ccc3o2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 10/20 0.52
▸ GLP1R P43220 1/20 0.51
▸ HDAC3 O15379 2/20 0.43
▸ HDAC1 Q13547 2/20 0.43
▸ HDAC2 Q92769 2/20 0.43
▸ HDAC4 P56524 1/20 0.42
▸ HDAC7 Q8WUI4 1/20 0.42
▸ HDAC10 Q969S8 1/20 0.42
▸ HDAC11 Q96DB2 1/20 0.42
▸ HDAC8 Q9BY41 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ HDAC9 Q9UKV0 1/20 0.42
▸ HDAC5 Q9UQL6 1/20 0.42
▸ ITGB3 P05106 3/20 0.40
▸ ITGA2B P08514 3/20 0.40
▸ TMEM97 Q5BJF2 1/20 0.40
▸ SIGMAR1 Q99720 1/20 0.40
▸ BCAT1 P54687 1/20 0.39
▸ LMNA P02545 1/20 0.39
▸ GIPR P48546 4/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2663584 0.89 GCGR (0.63) GCGRGLP1RHDAC3HDAC1HDAC2
SCHEMBL13800474 0.82 GCGR (0.61) GCGRGLP1RHDAC3HDAC1HDAC7
SCHEMBL2663347 0.80 GCGR (0.56) GCGRGLP1RHDAC3HDAC1HDAC2
SCHEMBL4081595 0.78 GCGR (0.80) GCGRGLP1RTMEM97SIGMAR1GIPR
SCHEMBL2663009 0.76 GCGR (0.79) GCGRGLP1RHDAC3HDAC1HDAC7
SCHEMBL13800470 0.75 HDAC1 (0.58) GCGRGLP1RHDAC3HDAC1HDAC2
SCHEMBL4091957 0.74 GCGR (0.64) GCGRGLP1RHDAC3HDAC1HDAC2
SCHEMBL13800468 0.74 GCGR (0.53) GCGRGLP1RHDAC3HDAC1HDAC7
SCHEMBL2662297 0.74 GCGR (0.54) GCGRGLP1RHDAC3HDAC1HDAC2
SCHEMBL2663429 0.73 GCGR (0.54) GCGRGLP1RGIPRADCY6ADCY3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GLP1R 1/4885HDAC3 1068/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885GLP1R 1/4885HDAC3 1068/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GLP1R 1/4885HDAC3 1068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.